A.Z. Isyangulova, R.Sh. Khasanov

Tatarstan Cancer Center, Kazan

Isyangulova Аlina Z. ― oncologist of the Tatarstan Cancer Center

29 Sibirskiy Tract, Kazan, Russian Federation, 420029, tel. +7-987-222-58-11, e-mail:, SPIN-code: 2245-6327

Abstract. Treatment advances have increased survival and duration of the relapse-free period in patient with cancer. Modern treatment involves risks, the most common among them is cardiotoxicity. This article presents the mechanisms for the development of type I and II cardiotoxicity and their differences on the example of drugs used in the treatment of breast cancer (anthracyclines and a targeted treatment ― trastuzumab). Diagnostic methods, their advantages and disadvantages, algorithm of diagnosis and continuation of therapy of patients receiving cardiotoxic therapy of breast cancer are presented. In all cases, it is necessary to adhere to the principle of «do no harm» and patients who are undergoing or have already undergone chemotherapy treatment should be recommended a visit to a cardiologist, examination and treatment with drugs with proven effectiveness.

Key words: chemotherapy, targeted therapy, cardiotoxicity, echocardiography, doxorubicine, trastuzumab, cardiomyopathy, cardiovascular complications.